Cell and Gene Therapy Market - Global Outlook and Forecast 2020-2025

CELL AND GENE THERAPY MARKET SIZE TO CROSS $14 BILLION BY 2025, GROWING AT A CAGR OF OVER 30% DURING THE FORECAST PERIOD.

Cell and Gene Therapy Market Size, Share, & Trends Analysis Report by Product (Cell and Gene Therapy), Disease (Dermatology, Musculoskeletal, Oncology, Genetic Disorders, and Others), End-users (Hospitality, Cancer Care Centers, Wound Care Centers, Ambulatory Surgical Centers, and Others), and Geography (North America, APAC, Europe, Latin America, and the Middle East & Africa) Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020–2025

MARKET DYNAMICS

The global cell and gene therapy market is one of the fastest-growing segments in the regenerative medicine market. The market is expected to grow at a faster pace during the forecast period. The demand can be attributed to the growing prevalence of several chronic diseases such as cancer, cartilage related problems, wounds, diabetic foot ulcer, genetic disorders, and other rare diseases across the globe. The prevalence of cancer and diabetes is increasing in the global population, which is influencing the growth of the market. There is a large unmet need in the treatment available, which is filled by cell and gene therapies. The market is growing due to the increased availability of funding from various public and private institutions. Besides, there is increased support from regulatory bodies for product approval. Several governments are creating awareness of cell and gene therapies in the population.

Snippets

• The gene therapy segment is expected to reach revenues of over $11 billion by 2025 due to the increased clinical efficacy of gene therapies to treat heart failures and other diseases.
• The oncology segment is expected to reach $9.5 billion by 2025 on account of the high prevalence of cancer and other terminal illness.
• The hospital segment is likely to observe an incremental growth of over $6 billion by 2025 due to the availability of advanced medical equipment and professionals.
• North America is likely to register revenues of over $11.5 billion by 2025, driven by the high prevalence of diabetes and cancer and other terminal diseases along with the high elderly population.

GLOBAL CELL AND GENE THERAPY MARKET REPORT SCOPE

CELL AND GENE THERAPY MARKET SEGMENTATION

This research report includes a detailed segmentation by product, disease, end-user, and geography.

INSIGHTS BY PRODUCT

The gene therapy segment is projected to grow at the highest CAGR during the forecast period

In 2019, the cell therapy segment accounted for a market share of over 53% in the global cell and gene therapy market. The segment is expected to grow at a steady rate during the forecast period due to the increase in the target population and the rise in the number of countries preferring cell therapies in their patients. Increased therapeutic benefits are attracting several countries to invest in this technology and conduct a high number of clinical trials. However, the lack of advanced infrastructure in developing countries is hindering the growth of the segment.

The gene therapy segment is expected to witness the fastest growth than cell therapy in the market. The high potential of treating diseases through gene therapies makes them more demanding than cell therapies. However, the lack of reimbursement is one of the significant challenges is limiting the usage of the cell and gene therapy segments.

INSIGHTS BY DISEASE

The genetic disorder segment is likely to register a staggering CAGR of close 35% during 2019­–2025

In 2019, the oncology segment accounted for a share of over 40% in the global cell and gene therapy market. Oncology has been one of the targets of intense research for the gene therapy procedures & approach. More than 60% of on-going gene therapy clinical trials are targeting cancer. The segment is expected to grow at a promising rate on account of the high prevalence of cancer diseases, especially in low and middle-come countries. The market is growing at a double-digit CAGR, which is expected to help the segment as many cell and gene therapy for cancer are commercially available.

The dermatology application segment in the cell and gene therapy includes wound care management among patients. Vendors are focusing on the development and commercialization of advanced wound care products for the treatment of chronic and acute wounds, thereby increasing the growth of the wound care market. The increased pervasiveness of diabetics is increasing acute and chronic wounds, including surgical wounds, pressure ulcers, diabetic foot ulcers, and other wounds.

The musculoskeletal segment is growing at a significant rate due to several factors, including an increase in the elderly population, growth in surgical volumes due to a high incidence of comorbidities and chronic inflammatory and degenerative conditions, such as osteoarthritis (OA) and tendonitis. At the same time, developed countries have started using cell therapy for the treatment of musculoskeletal disorders. Developing and underdeveloped countries are slowly adopting the usage of cell therapy.

INSIGHTS BY END-USERS

The hospital segment is projected to reach revenues of over $7 billion by 2025

In 2019, the hospital segment accounted for a share of over 40% in the global cell and gene therapy market. The market is growing due to the increasing incidence/prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, chronic wounds due to diabetes foot, pressure ulcers, and other injuries. More patients would be admitted to hospital premises with an increased prevalence rate of these diseases.

In 2019, the wound care segment accounted for a share of over 16% in the global market. Most patients suffer from chronic wounds such as diabetic ulcers, pressure ulcers, and venous stasis ulcers, cause significant morbidities in millions of patients per year. Hence, individuals who have diabetes for a long period develop both peripheral vascular disease and peripheral neuropathy. The majority of healthcare professionals prefer to use gene therapy in humans for better healing. This is driving the demand for gene therapy process in wound management, especially in wound care centers. 

The cancer care centers end-user segment is expected to grow at a significant rate as the number of people who have cancer is increasing across the globe. One of the major advantages of specialized cancer care centers is the availability of experienced and specialized care. Several new therapies are introduced to patients through cancer care centers. There are many investigational studies conducted in cancer care centers for future new therapy launches. With advances in cancer care treatments, and the need for timely treatment delivery, the importance of cancer care centers is increasing each day.

INSIGHTS BY GEOGRAPHY

North America will continue to dominate the global cell and gene therapy market share

In 2019, North America accounted for a share of over 60% of the global cell and gene therapy market. There are more than 530 regenerative medicine companies, including cell and gene therapy manufacturing developers. The number of products approved in North America grew significantly in 2019, with developers filed for marketing authorization for 10+ regenerative medicines, many of which we expect to be approved in 2020. Within the next 1–2 years, the number of approved gene therapies is expected to double. The US and Canada are the major contributors to the cell and gene therapy market in North America. Regulatory bodies are supporting several investigational products, fast track approvals, RMAT designation for the faster approval of the product into the market. The alliance for regenerative medicine and Medicare and Medicaid is working together to bring the structured reimbursement channels for cell and gene therapies.

INSIGHTS BY VENDORS

The global cell and gene therapy market is highly dynamic and characterized by the presence of several global, regional, and local vendors offering a wide range of therapies. Dendreon, Gilead Sciences, Novartis, Organogenesis, Osiris Therapeutics, Vericel, Amgen, and Spark Therapeutics are the leading players in the market with significant shares. Vendors such as NuVasive, APAC Biotech, Nipro, Orthocell, bluebird bio, J-TEC, and Terumo are the other prominent players in the market with a presence, especially in the cell therapy market. Most leading players are focusing on implementing strategies such as product launches and approvals, marketing and promotional activities, acquisitions, increased R&D investments, and strengthening their distribution networks to enhance their share and presence in the market.

The global cell and gene therapy market report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

By Product

• Cell Therapy
• Gene Therapy

By Disease

• Dermatology
• Musculoskeletal
• Oncology
• Genetic Disorders
• Others

By End-user   

• Hospitality
• Cancer Care Centers
• Wound Care Centers
• Ambulatory Surgical Centers
• Others

By Geography

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
• APAC
  • China
  • Japan
  • South Korea
  • Australia
  • India
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa
  • Saudi Arabia
  • Turkey
  • South Africa
  • UAE

KEY QUESTIONS ANSWERED

1. What is the cell and gene therapy market size and growth rate during the forecast period?
2. What are the factors impacting the growth of the cell and gene therapy market share?
3. How is the growth of the healthcare segment affecting the growth of the cell and gene therapy market?
4. Who are the leading vendors in the cell and gene therapy market, and what are their market shares?
5. Which product type/ end-user type/region is generating the largest revenue in the Asia Pacific region?